Compare Asana Inc. (ASAN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs BIO-TECHNE Corp — how do they compare? Asana Inc. trades at $9.16 (market cap $2.13B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 5.3× Asana Inc.'s market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | TECH | |
|---|---|---|
Market Cap | $2.13B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $72.29 |
52-Week Low | $5.46 | $43.31 |
Enterprise Value | $1.95B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.26, up 6.68% today, with a bullish technical signal from moving averages and a consensus price target of $10.33. Recent quarterly earnings have consistently beaten expectations, including Q1 2027 EPS of $0.10 versus $0.08 expected. Revenue growth is steady, reaching $724 million in 2025, but profitability remains negative with a net margin of -20.21%. The company is advancing its AI capabilities, highlighted by the StackAI acquisition announced on May 28, 2026.
The outlook is mixed: strong revenue growth and AI innovation support upside potential, but persistent losses and intense competition from Microsoft and Alphabet pose significant risks. Analyst sentiment is divided, with 42% buy ratings. Earnings momentum is key for sustained gains.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
